AN2 Therapeutics flagged new clinical and translational data supporting epetraborole as an oral candidate for polycythemia vera.
Results will be presented at the SOHO 2026 Annual Meeting on Sept. 9-12 in Houston.
Studies showed potential beneficial effects on red blood cell production and hemoglobin-related measures across healthy volunteers, non-PV patients, and primates.
Nonhuman primate exposure-response patterns aligned with effects later seen in humans, supporting translational relevance for ongoing development in PV.
ANTX•
